Miriplatin

Drug Profile

Miriplatin

Alternative Names: DACHPM; Miripla; Miriplatin hydrate; SM 11355; SMP 11355

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sumitomo Dainippon Pharma
  • Class Antineoplastics; Cyclohexanes; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatocellular carcinoma

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 20 Jan 2010 Launched for Hepatocellular carcinoma in Japan (Intrahepatic)
  • 16 Oct 2009 Registered for Hepatocellular carcinoma in Japan (Intrahepatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top